Director Douglas S. Miller filed a Form 4 with the SEC on November 6, 2026, disclosing the acquisition of 14,450 restricted stock units in Applied Digital Corp. granted on November 4, 2026 for board service.
Morgan Stanley Finance LLC filed a free writing prospectus on November 5, 2026, disclosing preliminary terms for Market Linked Securities linked to a basket of three equity indices and two ETFs, maturing November 21, 2031, and fully and unconditionally guaranteed by Morgan Stanley.
Crown PropTech Acquisitions filed Definitive Additional Materials (DEFA14A) on November 6, 2026, distributing a proxy card to shareholders ahead of an Extraordinary General Meeting scheduled for November 25, 2026, at 10:00 a.m. Eastern Time, to vote on a proposed business combination with Mkango Rare …
Lifetime Brands, Inc. filed an amendment to its current report on November 6, 2026, solely to add a previously omitted Adjusted EBITDA figure for the trailing twelve months ended September 30, 2026 to its earlier earnings release.
Utz Brands, Inc. filed its quarterly report on Form 10-Q with the SEC on November 6, 2026, covering the fiscal quarter ended September 27, 2026, disclosing share counts, company structure, and risk factors including a pending transaction with Intersnack Group GmbH & Co. KG.
The Bank of Nova Scotia filed a free writing prospectus on November 6, 2026, disclosing terms for Market Linked Securities auto-callable with contingent coupon and contingent downside linked to the lowest performing of Amazon.com, Alphabet, Microsoft, and NVIDIA, due November 15, 2029.
Protara Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 6, 2026, disclosing operational and financial information for the three and nine months ended September 30, 2026.
DRDGOLD Limited filed a Form 6-K on 6 November 2026 reporting that all ordinary and special resolutions put to shareholders at its annual general meeting held that same day were approved by the requisite majority.
Aligos Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 6, 2026, disclosing share counts, warrant positions, and its status as a clinical-stage biotechnology company with no approved products.
Argent Trust Company, as Trustee of the Sabine Royalty Trust, declared a cash distribution of $0.360390 per unit payable November 30, 2026, to unit holders of record on November 16, 2026, as announced on November 6, 2026.